Editor’s note: A livestream of this event will be embedded below at 1 p.m. ET.
It’s been almost a decade since the first stunning data on a cell therapy that battled blood cancer by genetically altering a patient’s own white blood cells to attack it. Many years and billions of dollars in mergers and acquisitions later, CAR-T is still used mostly as a last resort. Could new clinical trials that are about to report out in full change that? STAT gathers experts to look ahead.
- Sponsor Introduction: Anshul Mangal, president, Project Farma and Precision ADVANCE
- Daina Graybosch, Ph.D., senior research analyst at SVB Leerink
- Adam Feuerstein, senior writer, biotech, STAT (moderator)
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.